Phase I trial of SELK2 for Crohn's disease and multiple myeloma

Trial Profile

Phase I trial of SELK2 for Crohn's disease and multiple myeloma

Planning
Phase of Trial: Phase I

Latest Information Update: 12 May 2014

At a glance

  • Drugs SELK 2 (Primary)
  • Indications Crohn's disease; Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2014 New trial record
    • 06 May 2014 Selexys Pharmaceuticals has contracted Cytovance Biologics as its CMO to provide process development, scale up and cGMP manufacturing services of SELK2 in support of a phase I trial, according to a Cytovance Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top